{"count": 7, "results": [{"_id": "34420660", "pmid": 34420660, "title": "TAMEing ADPKD with metformin: safe and effective?", "journal": "Kidney Int", "authors": ["Ong ACM", "Gansevoort RT"], "date": "2021-09-01T00:00:00Z", "doi": "10.1016/j.kint.2021.07.021", "meta_date_publication": "2021 Sep", "meta_volume": "100", "meta_issue": "3", "meta_pages": "513-515", "score": 50277.66, "text_hl": "In this issue, Perrone et al. report results from the Trial of Administration of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in @<m>DISEASE_Familial_paroxysmal_dystonia</m> @DISEASE_MESH:C537180 @@@PKD@@@ (TAME @<m>DISEASE_Familial_paroxysmal_dystonia</m> @DISEASE_MESH:C537180 @@@PKD@@@) study, a phase 2 randomized controlled trial investigating the safety and tolerability of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @SPECIES_9606 @@@patients@@@ in the early stages of @DISEASE_Polycystic_Kidney_Autosomal_Dominant @DISEASE_MESH:D016891 @@@autosomal dominant polycystic kidney disease@@@. ", "citations": {"NLM": "Ong ACM, Gansevoort RT. TAMEing ADPKD with metformin: safe and effective? Kidney Int. 2021 Sep;100(3):513-515. PMID: 34420660", "BibTeX": "@article{34420660, title={TAMEing ADPKD with metformin: safe and effective?}, author={Ong ACM and Gansevoort RT}, journal={Kidney Int}, volume={100}, number={3}, pages={513-515}}"}}, {"_id": "34186056", "pmid": 34186056, "title": "Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).", "journal": "Kidney Int", "authors": ["Perrone RD", "Abebe KZ", "Watnick TJ", "Althouse AD", "Hallows KR", "Lalama CM", "Miskulin DC", "Seliger SL", "Tao C", "Harris PC", "Bae KT"], "date": "2021-09-01T00:00:00Z", "doi": "10.1016/j.kint.2021.06.013", "meta_date_publication": "2021 Sep", "meta_volume": "100", "meta_issue": "3", "meta_pages": "684-696", "score": 50275.617, "text_hl": "Primary results of the randomized trial of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ administration in @DISEASE_Polycystic_Kidney_Diseases @DISEASE_MESH:D007690 @@@polycystic kidney disease@@@ (TAME @<m>DISEASE_Familial_paroxysmal_dystonia</m> @DISEASE_MESH:C537180 @@@PKD@@@).", "citations": {"NLM": "Perrone RD, Abebe KZ, Watnick TJ, Althouse AD, Hallows KR, Lalama CM, Miskulin DC, Seliger SL, Tao C, Harris PC, Bae KT. Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int. 2021 Sep;100(3):684-696. PMID: 34186056", "BibTeX": "@article{34186056, title={Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).}, author={Perrone RD and Abebe KZ and Watnick TJ and Althouse AD and Hallows KR and Lalama CM and Miskulin DC and Seliger SL and Tao C and Harris PC and Bae KT}, journal={Kidney Int}, volume={100}, number={3}, pages={684-696}}"}}, {"_id": "37653564", "pmid": 37653564, "pmcid": "PMC10471794", "title": "Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease", "journal": "Physiol Rep", "authors": ["Oto OA", "Atwood DJ", "Chaudhary A", "He Z", "Li AS", "Wempe MF", "Edelstein CL"], "date": "2023-09-01T00:00:00Z", "doi": "10.14814/phy2.15776", "meta_date_publication": "2023 Sep", "meta_volume": "11", "meta_issue": "17", "meta_pages": "e15776", "score": 50270.33, "text_hl": "Therapeutic blood levels of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ did not slow @<m>DISEASE_Familial_paroxysmal_dystonia</m> @DISEASE_MESH:C537180 @@@PKD@@@. ", "citations": {"NLM": "Oto OA, Atwood DJ, Chaudhary A, He Z, Li AS, Wempe MF, Edelstein CL. Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease Physiol Rep. 2023 Sep;11(17):e15776. PMID: 37653564", "BibTeX": "@article{37653564, title={Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease}, author={Oto OA and Atwood DJ and Chaudhary A and He Z and Li AS and Wempe MF and Edelstein CL}, journal={Physiol Rep}, volume={11}, number={17}, pages={e15776}}"}}, {"_id": "36938071", "pmid": 36938071, "pmcid": "PMC10014337", "title": "Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants", "journal": "Kidney Int Rep", "authors": ["Hallows KR", "Abebe KZ", "Li H", "Saitta B", "Althouse AD", "Bae KT", "Lalama CM", "Miskulin DC", "Perrone RD", "Seliger SL", "Watnick TJ"], "date": "2022-12-05T00:00:00Z", "doi": "10.1016/j.ekir.2022.11.019", "meta_date_publication": "2023 Mar", "meta_volume": "8", "meta_issue": "3", "meta_pages": "467-477", "score": 50269.29, "text_hl": "Association of Longitudinal Urinary Metabolic Biomarkers With @DISEASE_Polycystic_Kidney_Autosomal_Dominant @DISEASE_MESH:D016891 @@@ADPKD@@@ Severity and Response to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in TAME-@<m>DISEASE_Familial_paroxysmal_dystonia</m> @DISEASE_MESH:C537180 @@@PKD@@@ Clinical Trial Participants", "citations": {"NLM": "Hallows KR, Abebe KZ, Li H, Saitta B, Althouse AD, Bae KT, Lalama CM, Miskulin DC, Perrone RD, Seliger SL, Watnick TJ. Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants Kidney Int Rep. 2023 Mar;8(3):467-477. PMID: 36938071", "BibTeX": "@article{36938071, title={Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants}, author={Hallows KR and Abebe KZ and Li H and Saitta B and Althouse AD and Bae KT and Lalama CM and Miskulin DC and Perrone RD and Seliger SL and Watnick TJ}, journal={Kidney Int Rep}, volume={8}, number={3}, pages={467-477}}"}}, {"_id": "34316721", "pmid": 34316721, "title": "Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants.", "journal": "Kidney360", "authors": ["Hallows KR", "Althouse AD", "Li H", "Saitta B", "Abebe KZ", "Bae KT", "Miskulin DC", "Perrone RD", "Seliger SL", "Watnick TJ"], "date": "2021-05-01T00:00:00Z", "doi": "10.34067/KID.0005962020", "meta_date_publication": "2021 May", "meta_volume": "2", "meta_issue": "5", "meta_pages": "795-808", "score": 50265.32, "text_hl": "BACKGROUND: Recent work suggests that dysregulated cellular metabolism may play a key role in the pathogenesis of @DISEASE_Polycystic_Kidney_Autosomal_Dominant @DISEASE_MESH:D016891 @@@autosomal dominant polycystic kidney disease@@@ (@DISEASE_Polycystic_Kidney_Autosomal_Dominant @DISEASE_MESH:D016891 @@@ADPKD@@@). The @<m>DISEASE_Familial_paroxysmal_dystonia</m> @DISEASE_MESH:C537180 @@@TAME-PKD@@@ clinical trial is testing the safety, tolerability, and efficacy of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, a regulator of cell metabolism, in @SPECIES_9606 @@@patients@@@ with @DISEASE_Polycystic_Kidney_Autosomal_Dominant @DISEASE_MESH:D016891 @@@ADPKD@@@. ", "citations": {"NLM": "Hallows KR, Althouse AD, Li H, Saitta B, Abebe KZ, Bae KT, Miskulin DC, Perrone RD, Seliger SL, Watnick TJ. Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants. Kidney360. 2021 May;2(5):795-808. PMID: 34316721", "BibTeX": "@article{34316721, title={Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants.}, author={Hallows KR and Althouse AD and Li H and Saitta B and Abebe KZ and Bae KT and Miskulin DC and Perrone RD and Seliger SL and Watnick TJ}, journal={Kidney360}, volume={2}, number={5}, pages={795-808}}"}}, {"_id": "40855441", "pmid": 40855441, "title": "Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): study protocol for a phase III, multi-centre, randomized, placebo-controlled trial evaluating the long-term efficacy of metformin in slowing the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.", "journal": "Trials", "authors": ["Pierre KS", "El-Damanawi R", "Johnson DW", "Hawley CM", "Viecelli AK", "Jha V", "Green SC", "Gesualdo L", "Kiriwandeniya C", "Velayudham P", "Vergara LA", "Mihala G", "Matsuyama M", "Brent PP", "Mallett AJ", "IMPEDE-PKD Global Steering Committee (see Appendix)"], "date": "2025-08-25T00:00:00Z", "doi": "10.1186/s13063-025-09010-6", "meta_date_publication": "2025 Aug 25", "meta_volume": "26", "meta_issue": "1", "meta_pages": "302", "score": 50251.355, "text_hl": "METHODS: IMPEDE-@<m>DISEASE_Familial_paroxysmal_dystonia</m> @DISEASE_MESH:C537180 @@@PKD@@@ is a prospective, multicentre, international, double-blind, randomized controlled trial of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ versus placebo in adults with @DISEASE_Polycystic_Kidney_Autosomal_Dominant @DISEASE_MESH:D016891 @@@ADPKD@@@. ", "citations": {"NLM": "Pierre KS, El-Damanawi R, Johnson DW, Hawley CM, Viecelli AK, Jha V, Green SC, Gesualdo L, Kiriwandeniya C, Velayudham P, Vergara LA, Mihala G, Matsuyama M, Brent PP, Mallett AJ, IMPEDE-PKD Global Steering Committee (see Appendix). Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): study protocol for a phase III, multi-centre, randomized, placebo-controlled trial evaluating the long-term efficacy of metformin in slowing the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease. Trials. 2025 Aug 25;26(1):302. PMID: 40855441", "BibTeX": "@article{40855441, title={Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): study protocol for a phase III, multi-centre, randomized, placebo-controlled trial evaluating the long-term efficacy of metformin in slowing the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.}, author={Pierre KS and El-Damanawi R and Johnson DW and Hawley CM and Viecelli AK and Jha V and Green SC and Gesualdo L and Kiriwandeniya C and Velayudham P and Vergara LA and Mihala G and Matsuyama M and Brent PP and Mallett AJ and IMPEDE-PKD Global Steering Committee (see Appendix)}, journal={Trials}, volume={26}, number={1}, pages={302}}"}}, {"_id": "34806449", "pmid": 34806449, "title": "Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.", "journal": "Am J Physiol Renal Physiol", "authors": ["Pastor-Soler NM", "Li H", "Pham J", "Rivera D", "Ho PY", "Mancino V", "Saitta B", "Hallows KR"], "date": "2022-01-01T00:00:00Z", "doi": "10.1152/ajprenal.00298.2021", "meta_date_publication": "2022 Jan 1", "meta_volume": "322", "meta_issue": "1", "meta_pages": "F27-F41", "score": 50247.78, "text_hl": "Altogether, these findings suggest several beneficial effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in this highly relevant slowly progressive @DISEASE_Polycystic_Kidney_Autosomal_Dominant @DISEASE_MESH:D016891 @@@ADPKD@@@ @SPECIES_10090 @@@mouse@@@ model, which may help inform new @DISEASE_Polycystic_Kidney_Autosomal_Dominant @DISEASE_MESH:D016891 @@@ADPKD@@@ therapies in @SPECIES_9606 @@@patients@@@.NEW & NOTEWORTHY @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ treatment improved @DISEASE_Polycystic_Kidney_Autosomal_Dominant @DISEASE_MESH:D016891 @@@ADPKD disease@@@ severity in a relevant, slowly progressive @DISEASE_Polycystic_Kidney_Autosomal_Dominant @DISEASE_MESH:D016891 @@@ADPKD@@@ @SPECIES_10090 @@@mouse@@@ model that recapitulates a @<m>DISEASE_Familial_paroxysmal_dystonia</m> @DISEASE_MESH:C537180 @@@PKD@@@-associated @GENE_PKD1 @GENE_18763 @@@PKD1@@@ mutation. ", "citations": {"NLM": "Pastor-Soler NM, Li H, Pham J, Rivera D, Ho PY, Mancino V, Saitta B, Hallows KR. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Am J Physiol Renal Physiol. 2022 Jan 1;322(1):F27-F41. PMID: 34806449", "BibTeX": "@article{34806449, title={Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.}, author={Pastor-Soler NM and Li H and Pham J and Rivera D and Ho PY and Mancino V and Saitta B and Hallows KR}, journal={Am J Physiol Renal Physiol}, volume={322}, number={1}, pages={F27-F41}}"}}]}